Kronox Lab

Who are the top shareholders of the Kronox Lab?

The top shareholders of Kronox Lab include promoter Jogindersingh G Jaswal with 26.39%, followed by individual investors with 20.54%, and the Negen Undiscovered Value Fund at 1.71%. Additionally, four Foreign Institutional Investors hold a combined 0.04% of the shares.

The top shareholders of Kronox Lab include the promoters, who hold the majority of the shares. The promoter with the highest holding is Jogindersingh G Jaswal, with a stake of 26.39%. Additionally, there are four Foreign Institutional Investors (FIIs) holding a combined 0.04% of the shares. The highest public shareholder is the Negen Undiscovered Value Fund, which holds 1.71%. Individual investors collectively own 20.54% of the company.

how big is Kronox Lab?

As of Jun 06, Kronox Lab Sciences Ltd has a market capitalization of 631.00 Cr, classifying it as a Micro Cap company, with recent net sales of 100.19 Cr and net profit of 25.47 Cr over the last four quarters. Shareholder's funds are valued at 66.31 Cr, with total assets of 73.61 Cr as of Mar'24.

Market Cap: As of Jun 06, Kronox Lab Sciences Ltd has a market capitalization of 631.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes Mar'25, Dec'24, Sep'24, and Jun'24, is 100.19 Cr. The sum of Net Profit for the same period is 25.47 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: This is based on Standalone data for the reporting period of Mar'24. Shareholder's Funds are valued at 66.31 Cr, and Total Assets amount to 73.61 Cr.

Has Kronox Lab declared dividend?

Kronox Lab Sciences Ltd has declared a 5% dividend, amounting to 0.5 per share, with an ex-date of August 23, 2024. Despite the dividend declaration, total returns have been mixed, showing significant negative returns in the short term and minimal returns over longer periods.

Kronox Lab Sciences Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 23 Aug 24<BR><BR>Dividend Yield: 0.29%.<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -16.64%, the dividend return was 0%, resulting in a total return of -16.64%.<BR><BR>For the 1-year period, the price return was 0%, the dividend return was 0.33%, leading to a total return of 0.33%.<BR><BR>In the 2-year period, both the price return and dividend return were 0%, resulting in a total return of 0.0%.<BR><BR>Over the 3-year period, there was no change in price or dividend return, maintaining a total return of 0.0%.<BR><BR>In the 4-year period, the price return and dividend return remained at 0%, resulting in a total return of 0.0%.<BR><BR>For the 5-year period, there was also no change in price or dividend return, leading to a total return of 0.0%.<BR><BR>Overall, while Kronox Lab has declared a dividend, the total returns over the various periods indicate a mixed performance, with significant negative returns in the short term and minimal returns over the longer term.

Is Kronox Lab overvalued or undervalued?

As of July 2, 2024, Kronox Lab is considered very expensive and overvalued with a PE ratio of 24.48, an EV to EBITDA of 18.54, and a Price to Book Value of 8.08, despite a year-to-date return of -15.17% compared to the Sensex's 5.54%.

As of 2 July 2024, the valuation grade for Kronox Lab has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios include a PE ratio of 24.48, an EV to EBITDA of 18.54, and a Price to Book Value of 8.08, which are notably high compared to industry norms.<BR><BR>In comparison to its peers, Kronox Lab's PE ratio is substantially lower than that of Solar Industries India Ltd. at 123.77 and Godrej Industries Ltd. at 46.63, but it remains elevated within its own valuation grade. The company's recent stock performance has been underwhelming, with a year-to-date return of -15.17%, contrasting sharply with the Sensex's positive return of 5.54% during the same period. This reinforces the notion that Kronox Lab is currently overvalued in the specialty chemicals sector.

Who are the peers of the Kronox Lab?

Kronox Lab's peers include Indokem, Nitta Gelatin, and Sudarshan Pharma, among others. Indokem has the highest 1-year return at 278.31%, while Black Rose Indus has the lowest at -25.91%, with Kronox Lab's return at 27.51%.

Peers: The peers of Kronox Lab are Indokem, Nitta Gelatin, DMCC Speciality, Jayant Agro Org., Chemcon Special., Sudarshan Pharma, Sunshield Chem., Nikhil Adhesives, Black Rose Indus, and Bhatia Colour.<BR><BR>Quality Snapshot: Excellent management risk is observed at Nitta Gelatin and Chemcon Special., while Average management risk is found at DMCC Speciality, Jayant Agro Org., Sudarshan Pharma, Sunshield Chem., Nikhil Adhesives, Black Rose Indus, and the rest. Below Average management risk is noted at Indokem and Bhatia Colour. In terms of Growth, Excellent growth is seen at Sudarshan Pharma, Good growth is found at Jayant Agro Org. and DMCC Speciality, while Below Average growth is noted at Indokem, Chemcon Special., Sunshield Chem., Nikhil Adhesives, Black Rose Indus, and the rest. Lastly, Excellent capital structure is observed at Nitta Gelatin and Chemcon Special., while Good capital structure is found at DMCC Speciality and Nikhil Adhesives, and Below Average capital structure is noted at Indokem, Sudarshan Pharma, Sunshield Chem., Black Rose Indus, and Bhatia Colour.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Indokem at 278.31%, while the peer with the lowest is Black Rose Indus at -25.91%. Kronox Lab's 1-year return of 27.51% is significantly lower than Indokem's but higher than Black Rose Indus's. Additionally, Sudarshan Pharma, Sunshield Chem., Nikhil Adhesives, and Black Rose Indus all have negative six-month returns.

What does Kronox Lab do?

Kronox Lab Sciences Ltd is a micro-cap company in the specialty chemicals industry, reporting net sales of 261 Cr and a net profit of 63 Cr for March 2025. It has a market cap of INR 711 Cr and key metrics include a P/E of 28.00 and a return on equity of 33.01%.

Overview:<BR>Kronox Lab Sciences Ltd operates in the specialty chemicals industry and is categorized as a micro-cap company.<BR><BR>History:<BR>Kronox Lab Sciences Limited was incorporated in 2008 as 'Kronox Lab Sciences Private Limited' and later converted into a Public Limited Company in 2019. The most recent quarterly results report net sales and profit for March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 261 Cr (Quarterly Results - Mar 2025)<BR>Net Profit: 63 Cr (Quarterly Results - Mar 2025)<BR>Market Cap: INR 711 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 28.00<BR>Industry P/E: 47<BR>Dividend Yield: 0.26%<BR>Debt Equity: -0.13<BR>Return on Equity: 33.01%<BR>Price to Book: 9.27<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Is Kronox Lab technically bullish or bearish?

As of October 8, 2025, Kronox Lab's technical trend has shifted to a bearish stance with moderate strength, indicated by bearish MACD, RSI, moving averages, and underperformance compared to the Sensex.

As of 8 October 2025, the technical trend for Kronox Lab has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include a bearish MACD on the weekly timeframe, a bearish RSI on the monthly timeframe, and bearish moving averages on the daily timeframe. Additionally, the KST is bearish on the weekly, and Dow Theory indicates a mildly bearish outlook on both weekly and monthly timeframes. The stock has underperformed significantly compared to the Sensex over various periods, further supporting the bearish sentiment.

How has been the historical performance of Kronox Lab?

Kronox Lab has demonstrated consistent growth over the past four years, with net sales increasing from 82.25 Cr in Mar'22 to 100.19 Cr in Mar'25, and profit after tax rising from 13.63 Cr to 25.47 Cr, reflecting strong profitability and improved cash flow. The company's total assets and liabilities also grew, indicating a stable financial position.

Answer:<BR>The historical performance of Kronox Lab shows a consistent growth in net sales and profitability over the past four years.<BR><BR>Breakdown:<BR>Kronox Lab's net sales have increased from 82.25 Cr in Mar'22 to 100.19 Cr in Mar'25, reflecting a positive growth trend. The total operating income followed a similar trajectory, rising from 82.25 Cr in Mar'22 to 100.19 Cr in Mar'25. The company's operating profit (PBDIT) also demonstrated significant growth, moving from 20.79 Cr in Mar'22 to 35.65 Cr in Mar'25, with an operating profit margin of 33.06% in the latest fiscal year. Profit before tax increased from 18.36 Cr in Mar'22 to 34.27 Cr in Mar'25, while profit after tax rose from 13.63 Cr to 25.47 Cr during the same period, resulting in a PAT margin of 25.42% in Mar'25. On the balance sheet, total assets grew from 56.46 Cr in Mar'22 to 98.43 Cr in Mar'25, with total liabilities increasing from 56.46 Cr to 98.43 Cr, indicating a stable financial position. Cash flow from operating activities improved significantly, reaching 30.00 Cr in Mar'25 compared to 9.00 Cr in Mar'22, while cash and cash equivalents at the end of Mar'25 stood at 3.00 Cr, up from 2.00 Cr in Mar'22. Overall, Kronox Lab has shown robust growth in sales, profits, and cash flow, alongside a strengthening balance sheet.

When is the next results date for Kronox Lab Sciences Ltd?

The next results date for Kronox Lab Sciences Ltd is 21 May 2026.

The next results date for Kronox Lab Sciences Ltd is scheduled for 21 May 2026.

Are Kronox Lab Sciences Ltd latest results good or bad?

Kronox Lab Sciences Ltd's latest results show a net profit increase of 21.40% and improved operating margins, but flat revenue growth raises concerns. Overall, the market sentiment is cautious, leading to a consensus "SELL" rating due to high valuation multiples.

Kronox Lab Sciences Ltd's latest results present a mixed picture. On one hand, the company reported a net profit of ₹8.00 crores for Q4 FY26, which is a significant increase of 21.40% compared to the previous quarter. Additionally, the operating margin improved to 36.43%, reflecting enhanced operational efficiency. However, the revenue for the same quarter remained flat at ₹26.13 crores, showing no year-on-year growth, which raises concerns about the company's ability to drive top-line expansion.<BR><BR>Despite the positive profit and margin improvements, the overall market sentiment appears cautious. The stock is currently trading at a price-to-earnings ratio of 19.25x and a price-to-book value of 5.53x, indicating a premium valuation that some analysts view as unjustified given the company's modest five-year sales growth rate of just 6.80%. This disconnect has led to a consensus "SELL" rating from the market.<BR><BR>In summary, while Kronox Lab has demonstrated strong profitability metrics and operational efficiency, the lack of revenue growth and high valuation multiples suggest that the latest results are not entirely positive, leading to a cautious outlook for the company.

Should I buy, sell or hold Kronox Lab Sciences Ltd?

Why is Kronox Lab Sciences Ltd falling/rising?

As of 03-Jun, the stock price of Kronox Lab Sciences Ltd is slightly rising at 134.05, but it has been on a downward trend with a total decline of -6.41% over the last four days. Despite today's minor uptick, the stock has underperformed against the Sensex and shows decreased investor interest.

As of 03-Jun, the stock price of Kronox Lab Sciences Ltd is experiencing a slight rise, currently at 134.05, with a change of 0.2 (0.15%) upward. However, it is important to note that the stock has been on a downward trend, having fallen consecutively for the last four days, resulting in a total decline of -6.41% during this period. <BR><BR>In the past week, the stock has underperformed compared to the benchmark Sensex, with a decline of -5.57% against the Sensex's -2.01%. Over the past month, the stock has also decreased by -4.82%, while the Sensex fell by -3.34%. Year-to-date, Kronox Lab Sciences Ltd has seen a decline of -3.60%, which is significantly better than the Sensex's -12.76% drop. However, over the past year, the stock has decreased by -21.22%, while the Sensex has only fallen by -7.92%.<BR><BR>Additionally, there is a notable decrease in investor participation, with the delivery volume dropping by -62.72% compared to the 5-day average, indicating reduced interest in trading the stock. The stock's performance today has underperformed its sector by -1.08%. <BR><BR>Overall, while there is a minor uptick in the stock price today, the broader context shows a significant decline in value and investor engagement, suggesting that the stock is still facing downward pressure despite the current rise.

Which are the latest news on Kronox Lab?